The week that closed June saw three Latin American regulators move to compress timelines, demonstrate authorization throughput, and stabilize leadership at the units sponsors care about most. Mexico confirmed a 30-day clinical-trial approval target. Brazil's ANVISA cleared twelve experimental molecules in one resolution. Argentina formalized leadership of its clinical trials department. Colombia's regulatory backlog became measurable for the first time in months.
Mexico · COFEPRIS · Brazil · ANVISA · Argentina · ANMAT · Colombia · INVIMA · Chagas · Roche · CRO
See workspace file /home/user/workspace/gta_linkedin_draft_2026-06-30.md for the 1280-word markdown body.
← All Global Trial Accelerators editions · Contact bioaccess®